<DOC>
	<DOCNO>NCT01163357</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Giving chemotherapy drug , fludarabine phosphate melphalan , total marrow irradiation donor peripheral blood stem cell transplant help stop growth cancer cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . PURPOSE : This phase I trial study side effect best dose bortezomib give together fludarabine phosphate melphalan without total marrow irradiation treat patient undergo donor peripheral blood stem cell transplant high-risk stage I II multiple myeloma .</brief_summary>
	<brief_title>Bortezomib , Total Marrow Irradiation , Fludarabine Phosphate , Melphalan Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I II Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility escalate dos bortezomib without total marrow irradiation ( TMI ) fix dose 900 cGy combination fludarabine ( FLU ) melphalan ( MEL ) preparative regimen allogeneic hematopoietic stem cell transplant patient high risk multiple myeloma human leukocyte antigen ( HLA ) match donor ( sibling match unrelated donor ) . II . To describe toxicity , maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) preparative regimen . SECONDARY OBJECTIVES : I . To evaluate frequency clinical response , i.e. , complete response [ CR ] , partial response [ PR ] , good partial response [ VGPR ] ) 6 month 1 year post transplant . II . To evaluate frequency primary secondary engraftment failure . III . To evaluate time neutrophil platelet engraftment . IV . To evaluate incidence acute chronic graft-versus-host disease ( GVHD ) . V. To evaluate progression-free survival . VI . To evaluate overall survival . VII . To evaluate minimal residual disease ( MRD ) 6 month 1 year post transplant flow cytometry bone marrow . OUTLINE : This dose-escalation study bortezomib . Patients assign 1 2 treatment group . GROUP I ( patient eligible TMI ) : Patients receive fludarabine phosphate intravenously ( IV ) day -9 -5 melphalan IV day -4 . Patients also undergo TMI twice daily ( BID ) day -9 -7 . If DLT observe first cohort , bortezomib IV add day -6 -3 subsequent cohort . . GROUP II ( patient ineligible TMI ) : Patients receive fludarabine phosphate IV melphalan IV Group I . Patients also receive bortezomib IV day -6 , -3 , 1 , 4 . TRANSPLANT : All patient undergo allogeneic peripheral blood stem cell ( PBSC ) transplant day 0 . GVHD PROPHYLAXIS : All patient receive tacrolimus IV orally ( PO ) sirolimus PO begin day -3 . After completion study treatment , patient follow day 100 , 6 month , annually thereafter .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Recipient must sign voluntary , informed consent accordance institutional federal guideline Recipients must histopathologically confirm diagnosis multiple myeloma Age : Stratum I ( TMI contain arm ) : 1860 year age Stratum II ( non TMI arm ) : 1870 year age Patients primary progressive disease induction therapy new targeted therapy Relapsed/refractory disease new targeted therapy , i.e . thalidomide , lenalidomide , bortezomib , new novel agent carfilzomib , pomalidomide Patients relapse multiple myeloma follow previous autologous stem cell transplant Plasma cell leukemia diagnosis Highrisk patient presence chromosome 17p deletion ( &gt; 60 % ) bone marrow fluorescence situ hybridization ( FISH ) ; patient require prior autologous stem cell transplant Able lie supine approximately 60 minute , anticipated duration treatment session Performance status evaluate Eastern Cooperative Oncology Group ( ECOG ) Karnofsky Performance Scales ( KPS ) patient must score 0II ( ECOG ) &gt; = 70 % ( KPS ) Cardiac ejection fraction &gt; = 50 % multiple gate acquisition ( MUGA ) scan and/or echocardiogram Forced expiratory volume one second ( FEV1 ) &gt; = 50 % Diffusing lung capacity carbon monoxide ( DLCO ) &gt; = 50 % Creatinine clearance glomerular filtration rate ( GFR ) &gt; = 60 ml/min Serum bilirubin = &lt; 2.0 mg/dl Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) = &lt; 2.5 time institutional upper limit normal Pretreatment test must perform within 30 day prior enrollment No medical psychosocial problem , opinion primary physician principal investigator would place patient unacceptable risk regimen Patients previous radiation maximum 2000 cGy non thoracicspine rib bone lesion &lt; 20 % bone marrow eligible TMI condition regimen Patients previous history irradiation dose thoracicspine , rib &gt; = 20 % bone marrow undergo TMI eligible bortezomib , fludarabine , melphalan regimen Stratum II ) ; patient enrol stratum II physician 's discretion patient decline radiation therapy DONOR : Any match sibling donor ( match HLA A , B , C intermediate resolution type HLADRB1 high resolution type ) , unmatched unrelated donor ( match HLA A , B , C , DRB1 high resolution type ) consider suitable donor Patients peripheral neuropathy great grade II Major medical psychiatric disorder would seriously compromise patient tolerance regimen Human immunodeficiency virus ( HIV ) infection , active hepatitis B C infection , evidence liver cirrhosis Active viral , bacterial fungal infection unless adequately treat . For fungal infection , patient complete full course antifungal therapy resolution infection . Patients radiographic change include pulmonary disease , include limited : pulmonary nodule , infiltrates , pleural effusion exclude unless clear pulmonary biopsy show evidence pulmonary infection Patients renal insufficiency cr clearance &lt; 60 ml/min DONOR : Donors exclude medical psychological reason unable tolerate procedure peripheral stem cell donation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>